Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Chakib Battioui"'
Autor:
Chakib Battioui, Albert Man, Melissa Pugh, Jian Wang, Xiangnan Dang, Hui Zhang, Paul Ardayfio, Leanne Munsie, Ann Marie Hake, Kevin M Biglan
Publikováno v:
Digital Biomarkers, Vol 7, Iss 1, Pp 54-62 (2023)
Introduction: PRESENCE was a phase 2 clinical trial assessing the efficacy of mevidalen, a D1 receptor positive allosteric modulator, for symptomatic treatment of Lewy body dementia (LBD). Mevidalen demonstrated improvements in motor and non-motor fe
Externí odkaz:
https://doaj.org/article/096624063c2b43e58a8c96931e5488eb
Autor:
Isabel Morales-Ivorra, Delia Taverner, Oriol Codina, Sonia Castell, Peter Fischer, Derek Onken, Píndaro Martínez-Osuna, Chakib Battioui, Manuel Alejandro Marín-López
Publikováno v:
Diagnostics, Vol 14, Iss 13, p 1394 (2024)
External validation is crucial in developing reliable machine learning models. This study aimed to validate three novel indices—Thermographic Joint Inflammation Score (ThermoJIS), Thermographic Disease Activity Index (ThermoDAI), and Thermographic
Externí odkaz:
https://doaj.org/article/fc38258878f5432784bc6840604ec45c
Autor:
Jian, Wang, Chakib, Battioui, Andrew, McCarthy, Xiangnan, Dang, Hui, Zhang, Albert, Man, Jasmine, Zou, Jeffrey, Kyle, Leanne, Munsie, Melissa, Pugh, Kevin, Biglan
Publikováno v:
Journal of Parkinson's Disease. 12:1991-2004
Background: PRESENCE was a Phase 2 trial assessing mevidalen for symptomatic treatment of Lewy body dementia (LBD). Participants received daily doses (10, 30, or 75 mg) of mevidalen (LY3154207) or placebo for 12 weeks. Objective: To evaluate if frequ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21da4750b94a0e49fe3f0876ab98e9b7
https://doi.org/10.3233/jpd-213126
https://doi.org/10.3233/jpd-213126
Autor:
Chen Chen, Nathan R. Kowahl, Erin Rainaldi, Maximilien Burq, Leanne M. Munsie, Chakib Battioui, Jian Wang, Kevin Biglan, William J. Marks, Ritu Kapur
Publikováno v:
Parkinsonism & Related Disorders. 109:105355
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9fb6a48a4d890b35169d99fd2e7b0bf4
https://doi.org/10.1016/j.parkreldis.2023.105355
https://doi.org/10.1016/j.parkreldis.2023.105355
Autor:
Vera Maljkovic, Chakib Battioui
Publikováno v:
Alzheimer's & Dementia. 16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d28b8242ccb7a2b342bef83c6379a9dd
https://doi.org/10.1002/alz.047027
https://doi.org/10.1002/alz.047027
Publikováno v:
Emerging Topics in Statistics and Biostatistics ISBN: 9783030401047
In contrast to the “one-size-fits-all” approach of traditional drug development, the paradigm of tailored therapeutics seeks to identify subjects with an enhanced treatment effect. In this chapter, we describe a statistical approach (TSDT) to sub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7bfc823e4bd6f3f7f54638bc3cf1f1a2
https://doi.org/10.1007/978-3-030-40105-4_8
https://doi.org/10.1007/978-3-030-40105-4_8
Autor:
Naga Chalasani, Thomas Hardy, Suman Duvvuru, Sudha S. Shankar, Anthony Akkari, Xiaotian Michelle Zhang, Sreekumar G. Pillai, Christof M. Kazda, Mark A. Deeg, Chakib Battioui, Pallav Bhatnagar, Wendra M. Foster, Cristina B. Guzman
Publikováno v:
Hepatology Communications. 2:561-570
LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29415cd08f7a70309a76379dfe48093e
https://doi.org/10.1002/hep4.1171
https://doi.org/10.1002/hep4.1171
Autor:
Markus Abt, B. Nhi Beasley, J. Rick Turner, Chakib Battioui, David H. Manner, Mary Jane Geiger, Stefan Hantel, Lee-Jen Wei
Publikováno v:
American heart journal. 215
Cardiovascular outcome trials (CVOTs) have been employed in multiple therapeutic areas to explore whether a noncardiovascular drug increases the risk for cardiovascular events. These studies are now a central part of drug development programs for ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fd441975211c57e9ad70994ab5e6341
https://pubmed.ncbi.nlm.nih.gov/31349109
https://pubmed.ncbi.nlm.nih.gov/31349109
Autor:
Chakib Battioui, Albert Lo, Sergey Shcherbinin, Michael C. Irizarry, Jian Wj. Wang, Ann Cleverly, Arnaud Charil, Bradley B. Miller, Stephen L. Lowe, Adam J. Schwarz, Jeffrey L. Dage
Publikováno v:
Alzheimer's & Dementia. 14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a21e7981fe02f44a037e1b6186306449
https://doi.org/10.1016/j.jalz.2018.06.333
https://doi.org/10.1016/j.jalz.2018.06.333
Autor:
Cristina B, Guzman, Suman, Duvvuru, Anthony, Akkari, Pallav, Bhatnagar, Chakib, Battioui, Wendra, Foster, Xiaotian Michelle, Zhang, Sudha S, Shankar, Mark A, Deeg, Naga, Chalasani, Thomas A, Hardy, Christof M, Kazda, Sreekumar G, Pillai
Publikováno v:
Hepatology Communications
LY2409021 is a glucagon receptor antagonist that was associated with hepatic steatosis and elevated aminotransferases in phase 2 diabetes studies. We investigated the relationship between selected genetic variants and hepatic steatosis and elevated a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c21c5df472239c63cea550f3a1dd7f95
https://pubmed.ncbi.nlm.nih.gov/29761171
https://pubmed.ncbi.nlm.nih.gov/29761171